ComFluCOV Study Results
The ComFluCOV study looked in to what side effects, such as fever and tiredness, people get when they are given their second dose of the COVID-19 vaccine at the same time as the currently recommended flu vaccines. The study also looked at people’s immune responses to both vaccines when given together.
The ComFluCOV study has shown that there are no safety concerns when COVID-19 and flu vaccines are given at the same time. You can read a summary of the results here.
Study Manager: Chloe Beard
Lung cancer is the most common cause of cancer death worldwide, and the majority of patients in the UK present with advanced disease. Although these new therapies are very good, residual advanced lung cancer persists in most patients after treatment and management of this is variable across the UK. Some patients receive only palliative care, while others may receive more aggressive treatment in the form of surgery, radiotherapy and/or ablation to remove all remaining cancer within the lung and throughout the body. Collectively, these more aggressive treatments are known as ‘local consolidative treatment’ (LCT). LCT is intensive, impacts quality of life and is expensive but, most importantly, we do not know whether it results in a better outcome for patients.
The aim of the RAMON study is to find out whether LCT is worthwhile (or not) for patients with residual advanced lung cancer. RAMON is a pragmatic, multi-centre, parallel group, randomised controlled trial that will run , with the primary outcome for the study being overall survival (minimum follow-up 2 years after randomisation). The set-up phase of the RAMON study began in August 2021 and we aim to recruit 244 patients over 3 years. We hope to recruit our first patient in April 2022!
You can read more on the RAMON study page.
This study is funded by the NIHR Health Technology Assessment Programme The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.